[Fundamental and clinical studies on T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
Fundamental and clinical studies on T-1982 (cefbuperazone) in the field of obstetrics and gynecology were carried out. Transfer of T-1982 to various location in uterus tissue was more than 10 micrograms/g over 2 hours after T-1982 1 g intravenous injection. T-1982 was distributed in cervix uteri at the highest concentration followed by ovarium, oviduct, portio vaginalis, endometrium and myometrium. Mean transfer ratio of cervix uteri to uterus arterial blood was 67.6%. Ten cases of gynecological infections receiving T-1982 demonstrated "good" results in 9 cases, except 1 case excluded from the evaluation of efficacy. Neither side effect nor clinical test abnormality was observed. Based on the results of basic and clinical studies, T-1982 is considered to have efficacy in the treatment of gynecological infections.
D000290:Adnexa Uteri / Q000032:analysis*; D000328:Adult; D000368:Aged; D002513:Cephamycins / Q000032:analysis* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D014599:Uterus / Q000032:analysis*; D014627:Vaginitis / Q000188:drug therapy; D014847:Vulvitis / Q000188:drug therapy
D002513:Cephamycins; C035978:cefbuperazone